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ABSTRACT
Objectives: To determine the most cost-effective strategy involving ﬁrst-
line treatment with long-acting risperidone, olanzapine, and quetiapine
from the perspective of the Chinese health-care system.
Methods: A decision analytical model was applied. The model used a time
horizon of 2 years. The probabilities of treatment response of different
agents and the relapse and hospitalization rates were estimated by a Delphi
panel of 17 senior psychiatrists in China. The unit cost for each medical
service was calculated from the price system database built by China
National Development and Reform Commission and the medical resource
utilization was estimated by the Delphi panel. The principal efﬁcacy
measure was the proportion of patients successfully treated. Various sen-
sitivity analyses were carried out to test the robustness of the model.
Results: The proportion of patients successfully treated over the 2-year
period was 46.71% for long-acting risperidone, 39.93% for olanzapine,
and 31.28% for quetiapine. The mean cost-effectiveness ratios were
RMB189,427, RMB202,432, and RMB233,015 per successfully treated
patient for long-acting risperidone, quetiapine and olanzapine, respec-
tively. Results of the sensitivity analyses conﬁrmed that the results were
robust.
Conclusions: The results showed that long-acting risperidone is more
cost-effective than olanzapine and quetiapine for patients with schizophre-
nia in long-term maintenance treatment.
Keywords: cost-effectiveness, decision tree, long-acting risperidone,
schizophrenia.
Introduction
Schizophrenia is a very serious mental illness [1] and is one of the
most expensive illnesses to treat [2]. A recent systematic review
of 158 studies found a median incidence rate of 15.2 per 100,000
[3]. Schizophrenia is also among the 15 leading causes of disabil-
ity and the top 10 leading causes of years lost due to disability
[4]. Empirical results from the reviewed studies indicate that the
negative economic consequences of mental illness far exceed the
direct cost of treatment, thus making it important to treat mental
illness [5]. In China, there are about 16 million patients suffering
from mental disorder [6] and almost half of them are attributed
to schizophrenia [7]. It is estimated that the annual economic
cost of schizophrenia exceeds RMB11 billion [8].
Relapse is the primary cost driver in schizophrenia and is
closely related to levels of adherence to therapy [9]. Both atypical
antipsychotic agents and depot preparations have been shown to
be useful in improving therapeutic adherence and cost saving
compared with oral conventional antipsychotic agents [10,11].
Long-acting risperidone is a new formulation of an atypical
antipsychotic agent that combines the pharmacological advan-
tages of the atypical drugs with those of a long-acting injectable
formulation, and has been shown to be efﬁcacious in short- and
long-term clinical trials by improving the patients’ compliance
and reducing relapse (For details, see Cost-Effectiveness of Long-
Acting Risperidone Value in Health Supporting Information, Part
I at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_Ming.asp.) [12,13]. The improved compliance com-
pared with existing treatment regimens implies that the higher
acquisition costs should be partially offset by reduced rates of
relapse. However, the long-acting injectable formulation has not
been widely used in China; only 61.8% of all patients with
schizophrenia use atypical antipsychotic agents and 6.5% use
depot antipsychotic medications in 2002 [14].
Despite the differences in costs and reimbursement structures
of the different health-care systems, a consistent overall conclu-
sion emerged from the different models that compare long-acting
risperidone with other oral atypical or conventional depot antip-
sychotic agents: long-acting risperidone reduces relapses and is,
thereby, cost saving [15–24]. However, there is limited research
on the cost-effectiveness of long-acting risperidone compared
with other treatment strategies in China.
Therefore, the aim of the present pharmacoeconomic evalu-
ation is to determine the most cost-effective pharmacological
treatment strategy for schizophrenic patients from three clinically
relevant options.
Methods
A decision tree model was created to compare the cost-
effectiveness of three ﬁrst-line treatment strategies in a sample of
young schizophrenic patients. It was carried out from the per-
spective of the Chinese health-care system over a 2-year period.
The study was conducted by an expert committee made up of 11
senior psychiatrists, two pharmacoeconomicists, and a health
economics expert from Xian-Janssen Pharmaceutical. The role of
the expert committee was to develop and validate a methodology
for use in this pharmacoeconomic assessment. Speciﬁcally, this
committee decided on the model type, target group (patient
population), effectiveness criteria, types of costs, clinical out-
comes, and variables to be tested in the sensitivity analyses.
Model Structure and Study Design
The decision tree model has three main branches corresponding
to the therapeutic strategies: long-acting risperidone injection,
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oral olanzapine, and oral quetiapine. Patients entering the model
are deﬁned by the expert panel as a group of stable schizophrenic
patients who met the Diagnostic and Statistical Manual of Mental
Disorders criteria for schizophrenia or schizoaffective disorder,
between 20 to 45 years old, treated for at least 1 year, and whose
disease had not been diagnosed for longer than 5 years and it has
the best therapeutic potential (For details, see Part II at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH12s3_
Ming.asp) [21,23].
The model structure was based on a model by De Graeve
et al. [21] and Yang et al. [23]. A time horizon of 2 years, divided
into six periods of 4 months each, was chosen. If the patient did
not respond to the therapy after 4 months of treatment, an
alternative therapy was proposed. A patient could receive four
different treatments before long-term hospitalization occurred.
The reappearance of positive symptoms, delusions, suicidal ide-
ation, or behavioral problems may prompt their physicians to
make a therapeutic change. The order of therapeutic changes
among the three different treatments was determined by the
expert committee (Table S1; see Part III at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_Ming.asp).
Clozapine is regarded as an atypical antipsychotic agent for use
only as second-line or subsequent treatment in China. Therefore,
in this study, it could only be offered as the fourth choice in a
sequence.
Deﬁnition of Health States and Efﬁcacy Criteria
The principal efﬁcacy measure was the proportion of patients
successfully treated, deﬁned as those who responded to initial
treatment and who had no more than two episodes of clinical
deterioration and did not need a change of treatment, over the 2
years [21,23].
Three different health states, clinical response, clinical dete-
rioration (CD), and inadequate response (IR), were deﬁned by
the expert panel, similar to the Taiwan study (Fig. S1; see Part IV
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_Ming.asp) [23].
The incidence of extrapyramidal side effects (EPS) and dosage
of each strategy in different mental states were determined by
the expert committee, who gave consensus estimates based
on literature review and on their own clinical experience
(Table S2; see Part V at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12s3_Ming.asp).
Data Sources
Information on therapeutic choices, transition probabilities
between health states, and the incidence of side-effects was
obtained from a 17-member expert panel of Chinese psychiatrists
(Delphi method) (for details, see Part VI at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_Ming.asp). Two
rounds of surveys were conducted in this Delphi panel. Only
minor ﬂuctuations of the parameter values were observed after
the second-round response.
The costs of the three states of response, CD, or IR were
estimated from the perspective of the Chinese health-care system.
We assumed that all patients in the target group should receive
psychiatric intervention during the 2-year period. The psychiatric
intervention included outpatient visit, emergency treatment,
emergency observation, day hospital, and hospitalization. The
unit cost for each medical procedure was calculated from the
price system database built by the China National Development
and Reform Commission and the utilization of ﬁve different
psychiatric interventions in each health state was acquired from
the 17-member Delphi panel. The cost of treating extrapyramidal
effects was added for all strategies, with the mean daily treatment
cost calculated on the basis of drug prescription data and using
the doses reviewed by the expert panel. All costs were discounted
at a rate of 3%.
Sensitivity Analysis
A decision analysis model was created using TreeAge Pro 2007
(TreeAge Software Inc., Williamstown, MA), which calculated
mean cost-effectiveness and incremental cost-effectiveness ratio
for each of the three treatment strategies. The C/E was expressed
as the cost per successfully treated patient. Two variables, price
of long-acting risperidone and the range of discount rate for
costs from 0% to 10%, were tested using one-way sensitivity
analysis.
Results
Efﬁcacy and Cost
Excluding medication cost, the average cost of outpatient visits
and emergency treatment were RMB177.62  188.39 and
177.94  129.66 (currently, $US1 = RMB6.8), respectively. The
average costs for emergency observation, day hospital, and hos-
pitalization per day were RMB291.92  158.13, RMB80.35 
39.50, and RMB691.64  628.53, respectively. The costs of the
three states of response, CD, or IR for a 4-month treatment were
RMB2577.92, RMB7061.29 and RMB12980.95, respectively.
Analysis of the response rate after 2 years of treatment found
that long-acting risperidone was the most effective strategy, with
46.71% of patients successfully treated after 2 years of treat-
ment, compared with 39.93% for olanzapine and 31.28%
for quetiapine. The mean cost per patient over 2 years was
RMB88,483 for long-acting risperidone, RMB93,055 for olan-
zapine, and RMB63,314 for quetiapine. And the mean C/Es were
RMB189,427, RMB233,015, and RMB202,432 per successfully
treated patient for long-acting risperidone, olanzapine, and
quetiapine, respectively. Despite the higher drug costs than que-
tiapine, long-acting risperidone was the dominant strategy
(Table S3; see Part VII at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH12s3_Ming.asp).
Sensitivity Analysis
The hypothesis was tested in the range of discount rate from 0%
to 10%. In each scenario, long-acting risperidone completely
dominated both the oral olanzapine and quetiapine strategies
(Fig. S2; see Part VIII at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH12s3_Ming.asp).
A sensitivity analysis of drug prices was also performed.
Assuming that the price of long-acting risperidone was decreased
or raised by 2%, 4%, 6%, 8%, or even 10%, long-acting
risperidone still emerged as the most cost-effective strategy
(Fig. S3; see Part IX at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12s3_Ming.asp).
Discussion
Schizophrenia is a severe and chronic illness as well as one of the
most expensive illnesses to treat. Relapse and rehospitalization
contribute signiﬁcantly to the economic burden of schizophrenia.
It is known that the relapse rate is 80% if a patient discontinues
his/her antipsychotics for more than 2 years [25]. Partial compli-
ancewith antipsychoticmedication is associatedwith an increased
risk of inpatient hospitalization [26]. Health care resource use is
signiﬁcantly reduced in patients with stable schizophrenia receiv-
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ing depot formulation [26].However, the high incidence of tardive
dyskinesia for conventional antipsychotics remains as the main
drawback for using conventional depot formulation in treating
schizophrenia [26]. The long-acting risperidone is an innovative
medicine that presents advantages not only improving compliance
but also decreasing the adverse effect that leads tomore reductions
of health-care resource and costs.
Previous cost-effectiveness analyses of long-acting risperidone
compared with oral olanzapine and haloperidol depot have
shown signiﬁcant cost savings associated with risperidone due to
improved efﬁcacy, and in particular, fewer EPS [16–23]. Those
results cannot be generalized for China, where the treatment
modalities and costs are different. Currently, the Positive and
Negative Syndrome Scale is often used to measure the efﬁcacy of
antipsychotics in China [14]. Haloperidol depot is not widely
used in China because of high incidence of EPS, and oral olan-
zapine and quetiapine are the main alternative options to long-
acting risperidone among the new generation of antipsychotics
for schizophrenia [14]. No study has been conducted to date to
compare the beneﬁts of long-acting atypical antipsychotics with
those of other atypical antipsychotics in China. Therefore, this
model simulation ﬁlls an important literature gap in China in this
regard.
We used an estimation method similar to that of a Belgian
study that used a simple decision tree as a model for the thera-
peutic management of schizophrenia [21]. Available literature
cannot supply all the data that are necessary to construct a
decision tree. As an alternative, an expert committee and ran-
domly selected psychiatrists provided estimates of the effective-
ness indicators for the models. All of our analyses showed that
the C/E of long-acting risperidone was lower than those of olan-
zapine and quetiapine. The robustness of the analytical model
was also validated by varying the price of long-acting risperidone
and the discount rate.
It is known that, in patients with schizophrenia, the total
health-care expenditure (including direct and indirect costs) is
signiﬁcantly higher than mental care cost alone [5]. However, it
is very difﬁcult to measure all direct medical and non-medical
costs for each of these medical problems, and loss of work day
induced by antipsychotics in China. Therefore, other than costs
for EPS, medical costs for other side effects of antipsychotics,
such as weight gain, sexual dysfunction, endocrine dysfunctions,
and cardiovascular problems, indirect cost such as productivity
loss were omitted. Thus the present cost ﬁgures are underesti-
mates of the actual costs of each strategy.
Another limitation of the study is the fact that the decision
tree analytical method inevitably runs the risk of simplifying a
complex reality. Patient response over different time frames is
indeed more complex in real life than in the choices portrayed in
this study. However, we believe that the decision times and
response patterns reasonably approximate this very complex
reality, as validated by an expert committee [21]. Similarly, the
assumption that long-term hospitalization would occur after four
therapeutic failures is based on the expert committee’s opinion.
Thus the results need to be conﬁrmed by a prospectively designed
study. Third, the study population, deﬁned as stable patients with
schizophrenia who were thought to be more responsive after
antipsychotic treatment, was a limited group of patients. There-
fore, caution must be taken before generalizing the results to all
patients.
Conclusion
The present study adds to a growing body of literature support-
ing the favorable cost effectiveness of long-acting risperidone for
the management of schizophrenia. All of the analyses showed
that the C/E of long-acting risperidone was lower (more cost-
effective) than those of olanzapine and quetiapine. Results of the
sensitivity analyses conﬁrmed the robustness of the model.
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